Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: The Pravastatin in Acute Coronary Treatment (PACT) trial

American Heart Journal

Volumn 148, Issue 1, 2004, Pages 91-

  Thompson, Peter L ^a,b   Meredith, Ian ^c   Amerena, John ^d   Campbell, Terence J ^e   Sloman, J Graeme ^f   Harris, Phillip J ^g  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f EPWORTH HOSPITAL   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRAVASTATIN;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT REFERRAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK REDUCTION; SIDE EFFECT; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; UNSTABLE ANGINA PECTORIS;

EID: 17944396864     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2003.10.052     Document Type: Article

References (31)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389
2. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 335:1996;1001-1009
3. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1996;1349-1357
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals a randomised placebo-controlled trial. Lancet. 360:2002;7-22
5. Sacks F.M. Lipid-lowering therapy in acute coronary syndromes. JAMA. 285:2001;1758-1760
6. Fonarow G.C., Ballantyne C.M. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease the time is now. Circulation. 103:2001;2768-2770
7. Stenestrand U., Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 285:2001;430-436
8. Newby L.K., Kristinsson A., Bhapkar M.V., et al. SYMPHONY and 2nd SYMPHONY Investigators Sibrafiban vs Aspirin to Yield Maximun Protection From Ischemic Heart Events Post-acute Coronary Syndromes: early statin initiation and outcomes in patients with acute coronary syndromes. JAMA. 287:2002;3087-3095
9. Arntz H.R., Agrawal R., Wunderlich W., et al. Beneficial effects of pravastatin (+/colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD]Study). Am J Cardiol. 86:2000;1293-1298
10. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 285:2001;1711-1718
11. Den Hartog F.R., Van Kalmthout P.M., Van Loenhout T.T., et al. Pravastatin in acute ischaemic syndromes results of a randomised placebo-controlled trial. Int J Clin Pract. 55:2001;300-304
12. Weissberg P., Clesham G.J., Bennett M.R. Is vascular smooth muscle cell proliferation beneficial? Lancet. 347:1996;305-307
13. Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 103:2001;276-283
14. Tsuda Y., Satoh K., Kitadai M., et al. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis. 122:1996;225-233
15. Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082
16. Lacoste J., Lam J.Y.T., Hung J., et al. Hyperlipidemia and coronary disease correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 92:1995;3172-3177
17. Puccetti L., Pasqui A.L., Pastorelli M., et al. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest. 32:2002;901-908
18. Perticone F., Ceravolo R., Maio R., et al. Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients. Atherosclerosis. 152:2000;511-518
19. Vita J.A., Yeung A.C., Winniford M., et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation. 102:2000;846-851
20. Dupuis J., Tardif J.C., Cernacek P., et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes the RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation. 99:1999;3227-3233
21. Kent S.M., Flaherty P.J., Coyle L.C., et al. Effect of atorvastatin and pravastatin on serum C-reactive protein. Am Heart J. 145:2003;e8
22. McKeown B., Thompson P.L. Early initiation of statin therapy after a coronary event. Curr Opin Lipidol. 13:2002;631-635
23. Liem A.H., van Boven A.J., Veeger N.J., et al. Fluvastatin On Risk Diminishment after Acute myocardial infarction study group effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J. 23:2002;1931-1937
24. Newby L.K., Kristinsson A., Bhapkar M.V., et al. SYMPHONY and 2nd SYMPHONY Investigators early statin initiation and outcomes in patients with acute coronary syndromes. JAMA. 287:2002;3087-3095
25. Cannon C.P., Braunwald E., McCabe C.H., et al. Pravastatin or atorvastatin evaluation and infection therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 350:2004;1495-1504
26. Blazing M.A., De Lemos J.A., Dyke C.K., et al. The A-to-Z trial methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of an early aggressive simvastatin therapy. Am Heart J. 142:2001;211-217
27. Fonarow G.C., French W.J., Parsons L.S., et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction data from the National Registry of Myocardial Infarction 3. Circulation. 103:2001;38-44
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III). JAMA. 285:2001;2486-2497
29. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). 2002. Available at: http://www.acc.org/ clinical/guidelines/unstable/unstable.pdf
30. Fonarow G.C., Gawlinski A., Moughrabi S., et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 87:2001;819-822
31. Lacy C.R., Suh D.C., Barone J.A., et al. Impact of a targeted intervention on lipid-lowering therapy in patients with coronary artery disease in the hospital setting. Arch Intern Med. 162:2002;468-473